ArticleImmunoTargets and therapy2017

Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer.

Mark Scholz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.